Asthmapolis is a San Francisco-based company that offers a digital therapeutic platform for patients with asthma and chronic obstructive pulmonary disease (COPD). Their FDA-cleared platform includes CE-marked sensors to track medication usage, a mobile app or online portal for personalized support and coaching, and tools for clinicians to monitor patient data. Asthmapolis aims to help patients identify triggers, reduce the use of rescue inhalers, and have more days with better breathing, ultimately allowing them to get back to doing the things they love.
Their platform also provides efficient care management and data-driven exacerbation prevention for clinicians, offering precise interventions and personalized experiences at scale. With a focus on education, support, and prevention, Asthmapolis empowers patients to take control of their health and helps prevent costly emergency room visits. Their platform is designed to benefit all partners in health, including payers, health systems, and life sciences, by reducing healthcare utilization and costs, improving care team efficiency, and enabling precision medication optimization.
Generated from the website